History - Suzhou Lixin Pharmaceutical Co., Ltd.

ABOUT US

Since established in 2000, Suzhou Lixin Pharmaceutical Co., Ltd. has been aimed at developing the global normative dominant market of characteristic APIs and advanced intermediates, driven by technological innovation, taken the path of sustainable development, and gradually formed the pharmaceutical product lines including anti-tumor, cardiovascular, antiviral and digestive system and other areas. Lixin has already become the high-quality supplier of many global pharmaceutical companies and has established the long-term relationship with a number of well-known domestic and foreign pharmaceutical companies to achieve win-win cooperation.

Enterprise strategy

Product Strategy

Standardized quality system and innovative technology make the quality of products always at the leading level in the industry.
Target Market

Focus on high added value new compounds, non-infringing new drugs and advanced intermediates in multiple markets.
Cost Strategy

Establish a complete industrial chain, optimize production efficiency, and effectively and reasonably control production costs.
Globalization Strategy

Focus on the regulatory market and cooperate with customers around the world with an open attitude.

History

2023

Shandong Lixin passed the on-site audit by US FDA, Suzhou Lixin passed the on-site audit by EDQM.

2022

Shandong Lixin obtain first CEP

2021

Shandong Lixin
passed the GMP On-site Inspection

2019-2020

Shandong Lixin was fully completed and put into production, and the regulatory registration of multiple products was started at the same time

2018

Shandong Lixin was rated as:
National Development and Reform Commission Strategic Emerging Industry Key Project, Shandong Province New and Old Kinetic Energy Conversion Key Project

2017

Shandong Lixin Pharmaceutical was established

2016

Passed EMA and EDQM on-site inspection for the first time

2015

Reviewed by FDA

Honor

The company adheres to the global regulatory pharmaceutical market, relying on the drive of scientific and technological innovation, persist on the concept of ecological civilization of safety and environmental protection, and insist on the path of green and sustainable development. It has gradually formed a high-end characteristic API product system in multiple fields such as anti-tumor, anti-virus, cardiovascular and cerebrovascular, and digestive system, and has become a API R&D and manufacturing enterprise with distinctive characteristics, reasonable layout, good reputation, specialization and precision, and a global High-quality suppliers and strategic partner of many pharmaceutical companies. It has recrived and many official certifications and honors such as High-tech enterprise in Jiangsu Province, private technology-based enterprise in Jiangsu Province, strategic emerging industry (project) enterprise in Taihu Lake Basin in Jiangsu Province, "specialized, new and special" enterprise in Jiangsu Province, intellectual property-intensive enterprise in Suzhou, and intellectual property-intensive enterprise in Suzhou Enterprises

Jiangsu High-Tech enterprise

Specialized, Special and New Enterprises in Jiangsu Province

Jiangsu Engineering Technology Research Center

Jiangsu Master Workstation

Private Technology Enterprise in Jiangsu Province

Suzhou Intellectual Property Intensive Enterprise